2w0j
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | [[Image:2w0j.png|left|200px]] | ||
- | |||
{{STRUCTURE_2w0j| PDB=2w0j | SCENE= }} | {{STRUCTURE_2w0j| PDB=2w0j | SCENE= }} | ||
- | |||
===CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH NSC 109555, A SPECIFIC INHIBITOR=== | ===CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH NSC 109555, A SPECIFIC INHIBITOR=== | ||
- | |||
{{ABSTRACT_PUBMED_19177354}} | {{ABSTRACT_PUBMED_19177354}} | ||
Line 14: | Line 10: | ||
==Reference== | ==Reference== | ||
- | <ref group="xtra">PMID:019177354</ref><ref group="xtra">PMID:017616632</ref><references group="xtra"/> | + | <ref group="xtra">PMID:019177354</ref><ref group="xtra">PMID:017616632</ref><references group="xtra"/><references/> |
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Non-specific serine/threonine protein kinase]] | [[Category: Non-specific serine/threonine protein kinase]] |
Revision as of 20:58, 24 March 2013
Contents |
CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH NSC 109555, A SPECIFIC INHIBITOR
Template:ABSTRACT PUBMED 19177354
About this Structure
2w0j is a 1 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA.
See Also
Reference
- Lountos GT, Tropea JE, Zhang D, Jobson AG, Pommier Y, Shoemaker RH, Waugh DS. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Sci. 2009 Jan;18(1):92-100. PMID:19177354 doi:10.1002/pro.16
- Jobson AG, Cardellina JH 2nd, Scudiero D, Kondapaka S, Zhang H, Kim H, Shoemaker R, Pommier Y. Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol Pharmacol. 2007 Oct;72(4):876-84. Epub 2007 Jul 6. PMID:17616632 doi:10.1124/mol.107.035832
Categories: Homo sapiens | Non-specific serine/threonine protein kinase | Jobson, A G. | Lountos, G T. | Pommier, Y. | Shoemaker, R H. | Tropea, J E. | Waugh, D S. | Zhang, D. | Chk2 inhibitor | Kinase | Li-fraumeni syndrome | Nucleotide-binding | Oncology | Serine/threonine-protein kinase | Structure-assisted drug design | Transferase